Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.
Suggest edits
Founded
2011
Raised
$98.1M
Follow us
Companies in the same industry
Alexa global traffic share
Twitter followers
Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2021
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 4

Add info
Add round
20 Jul 2017
$50,500,000
Venture capital (Series C)
NEA, Omega Funds, TPG Biotechnology Partners, +2

NEA leads $50.5 mln Series C round in Trevi Therapeutics

PE HUB
08 Jan 2015
$15,000,000
Debt financing
Square 1 Bank, Solar capital

Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics - News | ABL Advisor

abladvisor
06 Nov 2014
$26,000,000
Venture capital (Series B)
TPG Biotech
18 Dec 2012
$6,564,102
Venture capital